__timestamp | GSK plc | Takeda Pharmaceutical Company Limited |
---|---|---|
Wednesday, January 1, 2014 | 8246000000 | 612613000000 |
Thursday, January 1, 2015 | 9232000000 | 650773000000 |
Friday, January 1, 2016 | 9366000000 | 619061000000 |
Sunday, January 1, 2017 | 9672000000 | 628106000000 |
Monday, January 1, 2018 | 9915000000 | 717599000000 |
Tuesday, January 1, 2019 | 11402000000 | 964737000000 |
Wednesday, January 1, 2020 | 11456000000 | 875663000000 |
Friday, January 1, 2021 | 10975000000 | 886361000000 |
Saturday, January 1, 2022 | 8372000000 | 997309000000 |
Sunday, January 1, 2023 | 9385000000 | 1053819000000 |
Monday, January 1, 2024 | 1053819000000 |
In pursuit of knowledge
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, GSK plc and Takeda Pharmaceutical Company Limited have shown contrasting approaches. From 2014 to 2023, GSK's SG&A expenses fluctuated modestly, peaking in 2020 at approximately $11.5 billion before dropping to around $9.4 billion in 2023. In contrast, Takeda's expenses soared, starting at $612 billion in 2014 and reaching over $1 trillion by 2023, marking a staggering 72% increase.
This divergence highlights different strategic priorities. GSK's relatively stable expenses suggest a focus on cost control, while Takeda's rising costs may reflect aggressive expansion or investment in innovation. Notably, data for GSK in 2024 is missing, leaving room for speculation on future trends. As these giants navigate the evolving pharmaceutical landscape, their SG&A strategies will be pivotal in shaping their competitive edge.
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
5 Year Trend in Average Market Capitalization for AbbVie
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Number of Employees for Top 10 Healthcare Companies
Number of Employees for Top 10 Pharma Companies
Average Market Capitalization of Abbvie Annually
5 Year Trend in Market Capitalization for AbbVie
5 Year Trend in Average Market Capitalization for AbbVie
Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters